Table 3. Optimal amounts (for 2−2¹³ nmol), pertaining activities, absorbed doses and biologically effective doses (BED).

		Individual optimal amounta and individual activity for 10 Gy2.5 kidney BEDb and RM BED < 0.25 Gy15						Individual optimal amount and individual activity for 7.5 Gy salivary gland Db and RM BED < 0.25 Gy15
		Injection		Tumor		Salivary glands		Injection		Tumor		Kidneys
Patient	Tumor lesion	Activity[GBq]	Amount [nmol]	D[Gy]	BED[Gy3.9]	D[Gy]	BED[Gy4.5]	Activity[GBq]	Amount [nmol]	D[Gy]	BED[Gy3.9]	D[Gy]	BED [Gy2.5]
P1	1	22.5	512	156	234	10	11	16.5	512	114	156	5.7	6.9
	2	22.5	512	390c	850c	10	11	16.5	512	285	530	5.7	6.9
P2	1	13.9	64	46	52	20	24	4.4	2	23	24	4.3	4.9
	2	8.0	2	16	17	14	16	4.4	2	9.0	9.2	4.3	4.9
P3	1	14.1	256	171	223	40	53	4.3	512	33	35	1.6	1.6
	2	9.4	128	46	50	40	54	12.3	2048	8.6	8.7	1.8	1.9
P4	1	7.9	64	24	26	8.9	9.7	4.9	2	23	24	8.3	11
	2	7.9	64	14	14	8.9	9.7	4.9	2	13	14	8.3	11
P5	1	9.3	256	29	32	14	15	2.4	2	17	18	6.0	7.4
	2	9.3	256	42	47	14	15	8.2	512	23	25	4.4	5.1
Mean		12.5	211	93	154	18	22	7.9	411	55	84	5	6
SD		5.8	183	118	258	12	17	5.3	629	87	163	2	3
Median		9.3	192	44	48	14	15	4.9	257	23	24	5	6
Min		7.9	2	14	14	8.9	9.7	2.4	2	9	9	1.6	1.6
Max		22.5	512	390	850	40	54	16.5	2048	285	530	8	11

Abbreviations: D absorbed dose, BED biologically effective dose

^a1.66 μg of the ligand corresponds to 1 nmol. For these calculations, radiochemical limitations are not considered.

^b Kidney BED of 10 Gy_2.5 corresponds to a D of 7.9±0.2 Gy and salivary gland D of 7.5 Gy to a BED of 8.1±0.1 Gy_4.5

^cThe simulated absorbed dose is high due to high tumor binding site concentration (2412 ± 802 nmol/l) and large injected activity. Therefore, the BED calculated using the linear quadratic model becomes extremely large. The linear quadratic model is probably not applicable for such large doses.